



## ASX ANNOUNCEMENT

### CELLMID RECEIVES \$646K R&D TAX CREDIT

**SYDNEY, Thursday, 25 March 2021: Cellmid Limited (ASX: CDY)** advises that it has received \$645,748 from the Australian Taxation Office under the Research and Development Tax Incentive Scheme for the 2020 financial year.

The tax credit relates to research and development expenditure incurred by the Company in relation to its midkine and FGF5 inhibitor programmes.

Approved for release by the Board of Directors.

Contact:

Maria Halasz, CEO

T +612 9221 6830

#### **Cellmid Limited (ASX: CDY)**

Cellmid is a health and beauty-tech business growing shareholder value through the global distribution and sales of its proprietary brands of differentiated, clinically validated longevity and anti-aging solutions. Advangen Limited is Cellmid's wholly owned subsidiary engaged in the development and sale of first in class, best in class, clinically validated products for hair, skin and body. For further information, please see [www.cellmid.com.au](http://www.cellmid.com.au) and [www.evolisproducts.com.au](http://www.evolisproducts.com.au).

#### **Forward looking statements**

This announcement may have forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Cellmid to be materially different from the statements in this announcement. Actual results could differ materially depending on factors such as the availability of resources, regulatory environment, the results of marketing and sales activities and competition.